{
    "id": "dbpedia_219_3",
    "rank": 93,
    "data": {
        "url": "https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1506PP",
        "read_more_link": "",
        "language": "en",
        "title": "Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.atsjournals.org/pb-assets/images/logos/ATS_Logo_KeyOfferings_Journals_RGB-1630508770.svg",
            "https://www.atsjournals.org/pb-assets/images/logos/ATS_Logo_KeyOfferings_Journals_RGB-1630508770970.svg",
            "https://www.atsjournals.org/templates/jsp/images/orcid.png",
            "https://www.atsjournals.org/templates/jsp/images/orcid.png",
            "https://www.atsjournals.org/templates/jsp/images/orcid.png",
            "https://www.atsjournals.org/templates/jsp/images/icon_comment.png",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://www.atsjournals.org/na101/home/literatum/publisher/thoracic/journals/content/ajrccm/2020/ajrccm.2020.201.issue-4/rccm.201908-1506pp/20220531/images/medium/rccm.201908-1506pp_f1.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_up.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_up.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://www.atsjournals.org/na101/home/literatum/publisher/thoracic/journals/content/ajrccm/2020/ajrccm.2020.201.issue-4/rccm.201908-1506pp/20220531/images/medium/rccm.201908-1506pp_f2.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_up.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://www.atsjournals.org/na101/home/literatum/publisher/thoracic/journals/content/ajrccm/2020/ajrccm.2020.201.issue-4/rccm.201908-1506pp/20220531/images/medium/rccm.201908-1506pp_f3.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_up.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_up.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_up.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_up.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_up.gif",
            "https://www.atsjournals.org/templates/jsp/images/arrow_down.gif",
            "https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg",
            "https://www.atsjournals.org/pb-assets/images/logos/thoracic-logo-1698532980347.svg",
            "https://www.atsjournals.org/pb-assets/images/logos/COPE_Logo-1473694644763.png",
            "https://www.atsjournals.org/pb-assets/images/logos/Hinari_Logo-1473694644700.png",
            "https://www.atsjournals.org/pb%2Dassets/images/homepage/Footer/ACCME-commendation-full-color.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Liku B.  Tezera",
            "Salah  Mansour",
            "Paul  Elkington"
        ],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "/pb-assets/root_assets/favicon-1634685691147.ico",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "The global death toll from tuberculosis (TB) is an ongoing tragedy (1). Currently, clinicians in TB-prevalent resource-poor settings attempt to control the pandemic with clearly inadequate tools: bacillus Calmette-Guérin (BCG) vaccination, sputum smear microscopy, and antibiotic regimens of a minimum of 6 months, each of which has remained essentially unchanged for many decades (2). Although initial trials of novel vaccinations have been disappointing (3, 4), two recent vaccine trials have generated more promising results (5, 6). The M72/AS01E vaccine reduced the number of active cases by 50% in a phase 2b study (5), whereas a repeat BCG administration reduced sustained IFN-γ release assay conversion from 11.6% to 6.7% (6). Repeat BCG was not included in the first study, and so the relative efficacy cannot be defined. However, both studies demonstrate that a significant residual disease burden will persist, which can lead to ongoing transmission. Consequently, it is vital to consider what constitutes a protective immune response to Mycobacterium tuberculosis (Mtb) versus a pathological immune response that leads to cavitation and transmission (7). We review clinical and experimental observations that highlight the complexity of the host–pathogen interaction in human TB to develop an entirely new conceptual model that will inform future strategies.\n\n1. Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, et al. Tuberculosis: advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 2016;16:e34–e46. 2. Dheda K, Barry CE III, Maartens G. Tuberculosis. Lancet 2016;387:1211–1226. 3. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al.; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021–1028. 4. Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, et al.; MVA85A 030 Trial Investigators. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2015;3:190–200. 5. Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med 2018;379:1621–1634. 6. Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al.; C-040-404 Study Team. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 2018;379:138–149. 7. Ong CW, Elkington PT, Friedland JS. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am J Respir Crit Care Med 2014;190:9–18. 8. Brites D, Gagneux S. Co-evolution of Mycobacterium tuberculosis and Homo sapiens. Immunol Rev 2015;264:6–24. 9. Ghon A. The primary lung focus of tuberculosis in children. London: J. & A. Churchill; 1916. 10. Elkington PT, Friedland JS. Permutations of time and place in tuberculosis. Lancet Infect Dis 2015;15:1357–1360. 11. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol 2013;31:475–527. 12. Schreiber HA, Harding JS, Hunt O, Altamirano CJ, Hulseberg PD, Stewart D, et al. Inflammatory dendritic cells migrate in and out of transplanted chronic mycobacterial granulomas in mice. J Clin Invest 2011;121:3902–3913. 13. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009;136:37–49. 14. Esmail H, Riou C, Bruyn ED, Lai RP, Harley YXR, Meintjes G, et al. The immune response to Mycobacterium tuberculosis in HIV-1-coinfected persons. Annu Rev Immunol 2018;36:603–638. 15. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, Kremer K, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010;42:498–503. 16. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ 2018;362:k2738. 17. Yoder MA, Lamichhane G, Bishai WR. Cavitary pulmonary tuberculosis: the Holey Grail of disease transmission. Curr Sci 2004;86:74–81 18. Dubos R, Dubos J. The white plague: tuberculosis, man and society. New Brunswick, London: Rutgers University Press; 1987. 19. Sellors TH. The results of thoracoplasty in pulmonary tuberculosis. Thorax 1947;2:216–223. 20. Lenaerts A, Barry CE III, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev 2015;264:288–307. 21. Boisson-Dupuis S, Ramirez-Alejo N, Li Z, Patin E, Rao G, Kerner G, et al. Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a common TYK2 missense variant. Sci Immunol 2018;3:eaau8714. 22. Martínez-Barricarte R, Markle JG, Ma CS, Deenick EK, Ramírez-Alejo N, Mele F, et al. Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol 2018;3:eaau6759. 23. Karp CL, Wilson CB, Stuart LM. Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool. Immunol Rev 2015;264:363–381. 24. Kaufmann SH. A short history of Robert Koch’s fight against tuberculosis: those who do not remember the past are condemned to repeat it. Tuberculosis (Edinb) 2003;83:86–90. 25. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131–138. 26. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016;375:1767–1778. 27. Elkington PT, Bateman AC, Thomas GJ, Ottensmeier CH. Implications of tuberculosis reactivation after immune checkpoint inhibition. Am J Respir Crit Care Med 2018;198:1451–1453. 28. Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med 2019;11: eaat2702. 29. Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol 2011;186:1598–1607. 30. Lázár-Molnár E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci USA 2010;107:13402–13407. 31. Tzelepis F, Blagih J, Khan N, Gillard J, Mendonca L, Roy DG, et al. Mitochondrial cyclophilin D regulates T cell metabolic responses and disease tolerance to tuberculosis. Sci Immunol 2018;3:eaar4135. 32. Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 2015;47:242–249. 33. Lee RS, Proulx JF, Menzies D, Behr MA. Progression to tuberculosis disease increases with multiple exposures. Eur Respir J 2016;48:1682–1689. 34. Saunders MJ, Wingfield T, Tovar MA, Baldwin MR, Datta S, Zevallos K, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect Dis 2017;17:1190–1199. [Published erratum appears in Lancet Infect Dis 17:1117.] 35. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887–899. 36. Katsnelson A. Beyond the breath: exploring sex differences in tuberculosis outside the lungs. Nat Med 2017;23:398–401. 37. Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonça LE, Pacis A, et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 2018;172:176–190, e19 38. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012;109:17537–17542. 39. Netea MG, van Crevel R. BCG-induced protection: effects on innate immune memory. Semin Immunol 2014;26:512–517. 40. Hunter RL. Tuberculosis as a three-act play: a new paradigm for the pathogenesis of pulmonary tuberculosis. Tuberculosis (Edinb) 2016;97:8–17. 41. Elkington P, Tebruegge M, Mansour S. Tuberculosis: an infection-initiated autoimmune disease? Trends Immunol 2016;37:815–818. 42. Clayton K, Polak ME, Woelk CH, Elkington P. Gene expression signatures in tuberculosis have greater overlap with autoimmune diseases than with infectious diseases. Am J Respir Crit Care Med 2017;196:655–656. 43. Melandri D, Zlatareva I, Chaleil RAG, Dart RJ, Chancellor A, Nussbaumer O, et al. The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. Nat Immunol 2018;19:1352–1365. 44. Tatituri RV, Watts GF, Bhowruth V, Barton N, Rothchild A, Hsu FF, et al. Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs. Proc Natl Acad Sci USA 2013;110:1827–1832. 45. Van Rhijn I, van Berlo T, Hilmenyuk T, Cheng TY, Wolf BJ, Tatituri RV, et al. Human autoreactive T cells recognize CD1b and phospholipids. Proc Natl Acad Sci USA 2016;113:380–385. 46. Mansour S, Tocheva AS, Cave-Ayland C, Machelett MM, Sander B, Lissin NM, et al. Cholesteryl esters stabilize human CD1c conformations for recognition by self-reactive T cells. Proc Natl Acad Sci USA 2016;113:E1266–E1275. 47. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, Kawakami K, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007;178:3786–3796. 48. Peng MY, Wang ZH, Yao CY, Jiang LN, Jin QL, Wang J, et al. Interleukin 17-producing gamma delta T cells increased in patients with active pulmonary tuberculosis. Cell Mol Immunol 2008;5:203–208. 49. Maertzdorf J, Tönnies M, Lozza L, Schommer-Leitner S, Mollenkopf H, Bauer TT, et al. Mycobacterium tuberculosis invasion of the human lung: first contact. Front Immunol 2018;9:1346. 50. Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, et al. Commensal microbiota promote lung cancer development via γδ T cells. Cell 2019;176:998–1013, e16. 51. Di Marco Barros R, Roberts NA, Dart RJ, Vantourout P, Jandke A, Nussbaumer O, et al. Epithelia use butyrophilin-like molecules to shape organ-specific γδ T cell compartments. Cell 2016;167:203–218, e17 52. Lebrero-Fernández C, Wenzel UA, Akeus P, Wang Y, Strid H, Simrén M, et al. Altered expression of Butyrophilin (BTN) and BTN-like (BTNL) genes in intestinal inflammation and colon cancer. Immun Inflamm Dis 2016;4:191–200. 53. Divangahi M, Khan N, Kaufmann E. Beyond killing Mycobacterium tuberculosis: disease tolerance. Front Immunol 2018;9:2976. 54. Olive AJ, Sassetti CM. Tolerating the unwelcome guest; how the host withstands persistent Mycobacterium tuberculosis. Front Immunol 2018;9:2094. 55. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science 2012;335:936–941. 56. Garnier T, Eiglmeier K, Camus JC, Medina N, Mansoor H, Pryor M, et al. The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci USA 2003;100:7877–7882. 57. Evans JT, Smith EG, Banerjee A, Smith RM, Dale J, Innes JA, et al. Cluster of human tuberculosis caused by Mycobacterium bovis: evidence for person-to-person transmission in the UK. Lancet 2007;369:1270–1276. 58. Huang L, Nazarova EV, Tan S, Liu Y, Russell DG. Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny. J Exp Med 2018;215:1135–1152. 59. Simmons JD, Stein CM, Seshadri C, Campo M, Alter G, Fortune S, et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat Rev Immunol 2018;18:575–589. 60. Khader SA, Divangahi M, Hanekom W, Hill PC, Maeurer M, Makar KW, et al.; Bill and Melinda Gates Foundation Collaboration for TB Vaccine Discovery Innate Immunity Working Group18. Targeting innate immunity for tuberculosis vaccination. J Clin Invest 2019;129:3482–3491. 61. Andrews JR, Hatherill M, Mahomed H, Hanekom WA, Campo M, Hawn TR, et al. The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents. Am J Respir Crit Care Med 2015;191:584–591. 62. Elkington P, Lerm M, Kapoor N, Mahon R, Pienaar E, Huh D, et al. In vitro granuloma models of tuberculosis: potential and challenges. J Infect Dis 2019;219:1858–1866. 63. Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS One 2014;9:e87340."
    }
}